Journal: Cell Reports Methods

Article Title: In situ microwave fixation provides an instantaneous snapshot of the brain metabolome

doi: 10.1016/j.crmeth.2023.100455

Figure Lengend Snippet:

Article Snippet: GLUT3, Rabbit , Alomone , Cat# AGT-023; RRID:AB_2756644.

Techniques:

Journal: Alcohol and alcoholism (Oxford, Oxfordshire)

Article Title: Glycosylation is altered by ethanol in rat hippocampal cultured neurons.

doi: 10.1093/alcalc/agl044

Figure Lengend Snippet: Fig. 4. Western blot analysis of the glucose transporters GLUT1 and GLUT3 in control (CNT) and alcohol-exposed (EtOH) neurons. Histograms show increases in densitometric readings of GLUT1 and GLUT3 in alcohol-exposed cells compared with the controls. The data used for the statistical analysis are the mean ± SD of four independent experiments. Asterisks indicate significant differences (Student’s t-test P < 0.05).

Article Snippet: Antibodies: anti-MAP2 mouse monoclonal antibody (Sigma-Aldrich, Spain); anti-neurofilament (NF) 200 rabbit polyclonal antibody (Sigma-Aldrich); anti-GLUT1 rabbit polyclonal antibody (Santa Cruz Biotechnology, Inc. CA, USA), anti-GLUT3 rabbit polyclonal antibody (Santa Cruz Biotechnology, Inc.), anti-digoxigenin (DIG) mouse monoclonal antibody (Roche Diagnostics, S.L.

Techniques: Western Blot, Control

Journal: Channels

Article Title: Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma

doi: 10.1080/19336950.2023.2208928

Figure Lengend Snippet: SLC2A3 expression and correlation with survival status in HNSC. (a) SLC2A3 mRNA expression levels in pan-cancer data from TCGA. (b) Comparison of SLC2A3 mRNA expression levels between all normal tissues and HNSC samples from TCGA. (c) SLC2A3 mRNA expression in matched HNSC samples from TCGA. (d) the relationship between SLC2A3 mRNA expression and tumor stages of HNSC patients in the UALCAN database. The correlation between SLC2A3 expression and (e) disease-specific survival, (f) overall survival (OS) in TCGA and (G) OS in GSE65858. (h) ROC curve analysis of SLC2A3 diagnosis. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Article Snippet: After transfer, the membrane was incubated with primary antibodies against SLC2A3 (R24453, Zen Bio), E-cad (bs -10,009 R, Bioss), N-cad (bs-1172 R, Bioss), Vimentin (bs-0756 R, Bioss), Snai1 (bs-1371 R, Bioss), and NF-κB P65 (AP0123, ABclonal).

Techniques: Expressing, Comparison, Biomarker Discovery

Journal: Channels

Article Title: Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma

doi: 10.1080/19336950.2023.2208928

Figure Lengend Snippet: SLC2A3 expression was associated with the clinicopathological features of HNSC based on TCGA. (a) Univariate and (b) multivariate Cox analyses of SLC2A3 expression and clinicopathological variables. Kaplan – Meier analysis of overall survival for patients showed significant differences between high and low SLC2A3 expression groups with (c) T stage (d), N stage (e), M stage and (f) clinical stages.

Article Snippet: After transfer, the membrane was incubated with primary antibodies against SLC2A3 (R24453, Zen Bio), E-cad (bs -10,009 R, Bioss), N-cad (bs-1172 R, Bioss), Vimentin (bs-0756 R, Bioss), Snai1 (bs-1371 R, Bioss), and NF-κB P65 (AP0123, ABclonal).

Techniques: Expressing

Journal: Channels

Article Title: Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma

doi: 10.1080/19336950.2023.2208928

Figure Lengend Snippet: Enrichment analysis of the SLC2A3 gene coexpression network in HNSC. Heatmaps show the top 50 coexpressed genes (a) positively and (b) negatively correlated with SLC2A3 expression in HNSC. Enrichment analysis of (c) KEGG and (d – f) GO for SLC2A3 coexpression genes.

Article Snippet: After transfer, the membrane was incubated with primary antibodies against SLC2A3 (R24453, Zen Bio), E-cad (bs -10,009 R, Bioss), N-cad (bs-1172 R, Bioss), Vimentin (bs-0756 R, Bioss), Snai1 (bs-1371 R, Bioss), and NF-κB P65 (AP0123, ABclonal).

Techniques: Expressing

Journal: Channels

Article Title: Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma

doi: 10.1080/19336950.2023.2208928

Figure Lengend Snippet: SLC2A3 expression was correlated with EMT gene signatures in TCGA-HNSC. GSEA of DEGs between the low and high SLC2A3 expression groups from TCGA-HNSC for (a) activated pathways and (b) EMT gene signature. NES: normalized enrichment score. FDR: false discovery rate. (c-j) Correlation between SLC2A3 expression and EMT-related genes.

Article Snippet: After transfer, the membrane was incubated with primary antibodies against SLC2A3 (R24453, Zen Bio), E-cad (bs -10,009 R, Bioss), N-cad (bs-1172 R, Bioss), Vimentin (bs-0756 R, Bioss), Snai1 (bs-1371 R, Bioss), and NF-κB P65 (AP0123, ABclonal).

Techniques: Expressing

Journal: Channels

Article Title: Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma

doi: 10.1080/19336950.2023.2208928

Figure Lengend Snippet: SLC2A3 expression was associated with NF-κB, and NF-κB was associated with EMT gene signatures in TCGA-HNSC. (a) GSEA of DEGs between the low and high SLC2A3 expression groups from TCGA-HNSC for NF-κB signaling. NES: normalized enrichment score. FDR: false discovery rate. (b) Correlation between SLC2A3 and the expression of NF-κB1, NF-κB2, REL, RELA and RELB. (c) Both RELB and NF-κB2 were positively correlated with the expression of N-cad, vimentin, Snai1 and MMP9 and negatively correlated with the expression of E-cad.

Article Snippet: After transfer, the membrane was incubated with primary antibodies against SLC2A3 (R24453, Zen Bio), E-cad (bs -10,009 R, Bioss), N-cad (bs-1172 R, Bioss), Vimentin (bs-0756 R, Bioss), Snai1 (bs-1371 R, Bioss), and NF-κB P65 (AP0123, ABclonal).

Techniques: Expressing

Journal: Channels

Article Title: Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma

doi: 10.1080/19336950.2023.2208928

Figure Lengend Snippet: SLC2A3 expression was correlated with IL6/JAK/STAT3 signaling and interferon-γ hallmark gene sets. GSEA of DEGs between the low and high SLC2A3 expression groups from TCGA-HNSC for the (a) IL6/JAK/STAT3 signaling pathway and (b) interferon- γ response pathway. NES: normalized enrichment score. FDR: false discovery rate. (c-g) the positive correlation between SLC2A3 and the expression of CXCR4, CCR1, CCR, CCL2 and CCL13 based on TCGA-HNSC. (h) SLC2A3 knockdown inhibited the mRNA expression of CXCR4, CCR1, CCR8, CCL2, and CCL13. Each value represents the mean ± SD of three separate experiments. *P < 0.05; **P < 0.01.

Article Snippet: After transfer, the membrane was incubated with primary antibodies against SLC2A3 (R24453, Zen Bio), E-cad (bs -10,009 R, Bioss), N-cad (bs-1172 R, Bioss), Vimentin (bs-0756 R, Bioss), Snai1 (bs-1371 R, Bioss), and NF-κB P65 (AP0123, ABclonal).

Techniques: Expressing, Knockdown

Journal: Channels

Article Title: Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma

doi: 10.1080/19336950.2023.2208928

Figure Lengend Snippet: Correlation between SLC2A3 expression and tumor immune infiltrating cells. (a) Infiltration of 22 immune infiltrating cells between HNSC patients with low and high SLC2A3 expression obtained by CIBERSORTx. (b) Comparison of immune infiltrating cell levels in HNSC with different SLC2A3 CNVs. (c) Clinical survival outcome of HNSC patients with high B cell, CD8+ T-cell and myeloid dendritic cell infiltration. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Article Snippet: After transfer, the membrane was incubated with primary antibodies against SLC2A3 (R24453, Zen Bio), E-cad (bs -10,009 R, Bioss), N-cad (bs-1172 R, Bioss), Vimentin (bs-0756 R, Bioss), Snai1 (bs-1371 R, Bioss), and NF-κB P65 (AP0123, ABclonal).

Techniques: Expressing, Comparison

Journal: Channels

Article Title: Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma

doi: 10.1080/19336950.2023.2208928

Figure Lengend Snippet: Scatter plot of the relationship between SLC2A3 expression and drug sensitivity. SLC2A3 expression was (a, b, d-h, j-l) negatively or (c, i) positively correlated with the IC50 of drugs approved by the FDA. (M) Effect of obatoclax and triciribine on cell viability upon SLC2A3 knockdown. *P < 0.05.

Article Snippet: After transfer, the membrane was incubated with primary antibodies against SLC2A3 (R24453, Zen Bio), E-cad (bs -10,009 R, Bioss), N-cad (bs-1172 R, Bioss), Vimentin (bs-0756 R, Bioss), Snai1 (bs-1371 R, Bioss), and NF-κB P65 (AP0123, ABclonal).

Techniques: Expressing, Knockdown

Journal: Channels

Article Title: Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma

doi: 10.1080/19336950.2023.2208928

Figure Lengend Snippet: SLC2A3 knockdown inhibited proliferation and migration and NF-κB/EMT-related gene expression in FaDu and CNE-2 cell lines. (a) SLC2A3 mRNA expression in adjacent normal tissues (ANT) and HNSC samples. (b) Cell proliferation and (c) migration were suppressed upon SLC2A3 knockdown. (d) SLC2A3 knockdown inhibited N-cad, Vimentin, and Snai1 expression but increased E-cad expression. (e) NF-κB P65 expression was decreased upon SLC2A3 knockdown. Each value represents the mean ± SD of three separate experiments. * p < 0.05, # p < 0.01.

Article Snippet: After transfer, the membrane was incubated with primary antibodies against SLC2A3 (R24453, Zen Bio), E-cad (bs -10,009 R, Bioss), N-cad (bs-1172 R, Bioss), Vimentin (bs-0756 R, Bioss), Snai1 (bs-1371 R, Bioss), and NF-κB P65 (AP0123, ABclonal).

Techniques: Knockdown, Migration, Gene Expression, Expressing

Journal: Journal of translational medicine

Article Title: Apelin-13 attenuates optic nerve damage in glaucomatous mice by regulating glucose metabolism.

doi: 10.1186/s12967-025-06212-z

Figure Lengend Snippet: Fig. 4 Role of exogenous [Pyr1]-apelin-13 in glucose metabolism in retinal and brain neuronal cells. (A) GLUT1 expression in visual cortex neurons was elevated in the PECE group compared with the NC group, whereas it was lower in the Apelin-13 group than that in the PECE group. (B) The trend of GLUT3 expression in visual cortex neurons was consistent with that of GLUT1 expression. (C) G6PD expression in visual cortex neurons was lower in the PECE group than in the NC group, whereas G6PD expression was elevated in the Apelin-13 group compared with that in the PECE group. D a GLUT1, GLUT3, and G6PD expression in the retina. (D) b GLUT1 expression was decreased in the PECE group compared with the NC group and increased in the Apelin-13 group compared with that in the PECE group. (D) c GLUT3 expression was elevated in the PECE group compared with that in the NC group and decreased in the Apelin-13 group compared with the PECE group. (D) d G6PD expression was lower in the PECE group than in the NC group and increased in the Apelin-13 group compared with the PECE group. (E a GLUT1, GLUT3, and G6PD expression in the brain. (E) b c d Trend of GLUT1, GLUT3, and G6PD expression in the brain is consistent with that in the retinal tissues. *P < 0.05, **P < 0.01, ***P < 0.001. GLUT: glucose transporter; G6PD: glucose- 6-phosphate dehydrogenase; IOP: intraocular pressure; NC: normal control; PECE: PEG-PCL-PEG; RGCs: retinal ganglion cells

Article Snippet: The primary antibodies used were Iba1(1:200, anti-Iba1 antibody, Wako, 019-19741, Japan), NeuN (1:200, anti-NeuN antibody, Cell Signaling Technology, 94403 S, USA), GLUT1 (1:100, Novus, NB11039113, USA), GLUT3 (1:100, Novus, NBP3-12885, USA), and glucose-6-phosphate dehydrogenase (G6PD) (1:100, GeneTex, GTX101218, USA), followed by secondary antibodies (1:500, Bioworld, China).

Techniques: Expressing, Control

Journal: Journal of translational medicine

Article Title: Apelin-13 attenuates optic nerve damage in glaucomatous mice by regulating glucose metabolism.

doi: 10.1186/s12967-025-06212-z

Figure Lengend Snippet: Fig. 6 Effects of Apelin-13 on oxidative stress and the protein regulation and the PI3K/Akt pathway in retinal and brain neural tissue cells can be reversed by LY294002. (A) a NADPH levels in the retinal tissue were lower in the Apelin-13 group than in the PECE group, whereas they were higher in the LY294002 group than in the Apelin-13 group. (A) b NADPH levels in the brain tissues changed in the same pattern as those in the retinal tissues. (B) a ROS levels in the retinal tissues were lower in the Apelin-13 group than in the PECE group and higher in the LY294002 group. (B) b Trend of ROS levels in the brain tissues was the same as that in the retinal tissues. (C) The p-PI3K/PI3K and p-Akt/Akt ratios in the retinal tissues of mice were significantly higher in the Apelin-13 group than in the PECE group, whereas these ratios were reduced in the LY294002 group. (D) Alterations in p-PI3K/PI3K and p-Akt/Akt ratios in the brain tissues followed the same trend as observed in the retinal tissues. (E) a GLUT1, GLUT3, and G6PD expression in the retina. (E) b GLUT1 expression reduced in the LY294002 group compared with the Apelin-13 group. (E) c GLUT3 expression was increased in the LY294002 group compared with the Apelin-13 group. (E) d G6PD expression was reduced in the LY294002 group compared with the Apelin-13 group. (F) a GLUT1, GLUT3, and G6PD expres sion in the brain. (F b, c, d Trend of GLUT1, GLUT3, and G6PD expression in the brain was consistent with that in the retinal tissues. *P < 0.05, **P < 0.01, ***P < 0.001. Akt: protein kinase B; IOP: intraocular pressure; PI3K: phosphatidylinositol 3-kinase; RGCs: retinal ganglion cells; ROS: reactive oxygen species

Article Snippet: The primary antibodies used were Iba1(1:200, anti-Iba1 antibody, Wako, 019-19741, Japan), NeuN (1:200, anti-NeuN antibody, Cell Signaling Technology, 94403 S, USA), GLUT1 (1:100, Novus, NB11039113, USA), GLUT3 (1:100, Novus, NBP3-12885, USA), and glucose-6-phosphate dehydrogenase (G6PD) (1:100, GeneTex, GTX101218, USA), followed by secondary antibodies (1:500, Bioworld, China).

Techniques: Expressing